<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661059</url>
  </required_header>
  <id_info>
    <org_study_id>253088</org_study_id>
    <nct_id>NCT04661059</nct_id>
  </id_info>
  <brief_title>Study of Late-foetal Human Organ Development</brief_title>
  <official_title>Study of Late-foetal Human Organ Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College London Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knowledge about abnormal organ development is important to understand pathology and to&#xD;
      develop novel treatment approaches for individuals with congenital and acquired disease. Most&#xD;
      of our current understanding is based on examination of tissues from the embryo and early&#xD;
      fetus, collected from women undergoing termination of pregnancy in the first trimester&#xD;
      (third) of pregnancy. There is very little known about normal and abnormal organ development&#xD;
      from a developmental perspective during the crucial last two-thirds of pregnancy when much&#xD;
      remodelling of fetal tissues occurs. We aim to collect tissue from a variety of developing&#xD;
      fetal organs in the last two-thirds of pregnancy from women who decide to undergo a&#xD;
      termination of pregnancy and who wish to undergo a clinical fetal postmortem (PM)&#xD;
      examination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2040</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Cellular maturity</measure>
    <time_frame>Immediately after tissue collection</time_frame>
    <description>Immunofluorescence staining</description>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Congenital Disorders</condition>
  <eligibility>
    <study_pop>
      <textblock>
        As above&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥18 years old pregnant women who attend the Fetal Medicine Unit for concerns about a&#xD;
             fetal abnormality where they decide to proceed to termination of pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Screening labs positive for maternal HIV, Hepatitis B and Hepatitis C, Chlamydia and&#xD;
             Herpes.&#xD;
&#xD;
          -  Subject unable to make an informed decision about termination of pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College London Hospitals</investigator_affiliation>
    <investigator_full_name>Marko Nikolic</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

